Drug Profile
Research programme: intranasal dopamine - Acerus Pharmaceuticals
Alternative Names: Dopamine intranasal gel - Acerus Pharmaceuticals; TBS-3Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Trimel Pharmaceuticals Corporation
- Developer Acerus Pharmaceuticals
- Class
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinsonian disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinsonian disorders in Canada (Intranasal, Gel)
- 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
- 26 Aug 2011 Preclinical trials in Parkinsonian disorders in Canada (Intranasal)